2024-12-13 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Comparison & Divergence:**

Merck & Co Inc (MRK), a leading pharmaceutical company, has shown a cumulative return of 63.91% over the analyzed period.  Compared to the S&P 500 (VOO) with a cumulative return of 122.07%, MRK underperformed by 58.2 percentage points.  The relative divergence of -58.2 places it at the 4.9th percentile of the historical range of divergence between MRK and the S&P 500, indicating significantly lower performance than the benchmark index.  The provided CAGR data shows fluctuating performance over different time periods, highlighting the volatility of pharmaceutical sector returns.


**2. Recent Price Movement:**

* **Closing Price:** $99.75 (Last Market: $100.92)
* **5-day Moving Average:** $102.24
* **20-day Moving Average:** $100.27
* **60-day Moving Average:** $105.69

The price is currently below all three moving averages, suggesting a possible downward trend.  The recent closing price is slightly below the last market price.


**3. Technical Indicators & Expected Return:**

* **RSI:** 56.19 – Suggests neither overbought nor oversold conditions.
* **PPO:** 0.36 –  A positive value indicates bullish momentum, but the relatively low value suggests the momentum may be weakening.
* **20-Day Relative Divergence Change:** -2.4% – Indicates a recent short-term downward trend.
* **Expected Return:** 0.0% –  The provided expected return is 0%, meaning there's no projected outperformance compared to the S&P 500 over the long term (2+ years). This does not necessarily mean a negative return, but rather it should be interpreted as not exceeding the broader market's performance based on the given data.  The slight drop from last market price to closing price indicates a minor pullback, but this is not a dramatic change.

**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in both EPS and revenue.

* **Revenue:** While revenue fluctuates between $15.78B and $16.66B, it generally shows an upward trend over the observed period.
* **EPS:** EPS has also fluctuated, with the most recent quarter at $1.25, significantly lower than the $2.15 in the previous quarter. This large drop warrants further investigation outside the provided context.  There is also a duplication of the November 2024 entry.
* **Significant Changes:** The large drop in EPS from Q2 2024 to Q3 2024 is the most notable change.


**5. Financial Information Analysis:**

* **Revenue and Profitability:**  Revenue has generally been increasing, though the latest quarter shows a slight dip compared to previous quarters.  Profit margin shows some fluctuation but is generally high, although it has slightly decreased in the latest quarter.
* **Capital and Profitability:**  Equity has been increasing generally.  ROE has shown significant volatility, including a negative value in one quarter.


**6. News and Recent Issues:**

This section requires additional information.  No news or recent market outlook or analyst opinions are provided.

**7. Overall Analysis:**

MRK has underperformed the S&P 500 significantly over the analyzed period. Recent price action suggests a possible downward trend, supported by the movement below its moving averages.  While technical indicators aren't extremely bearish, they don't show strong bullish signals either.  The large drop in EPS in the latest quarter is concerning and requires further investigation.  The provided data shows fluctuating financial performance with some positive aspects such as high profit margins and generally increasing revenue. The lack of recent news and analyst opinions makes a comprehensive evaluation challenging.  More information is needed to make a fully informed investment decision.  The provided 0% expected return versus the S&P 500 suggests that investors should not anticipate outperformance of the market; however, this assumes a continued current trend and may not accurately reflect future performance.

**8. Disclaimer:** This analysis is based solely on the data provided.  It is not financial advice, and further research and consideration of other factors are crucial before making any investment decisions.  The missing context around news, analyst opinions, and the reasons for the EPS drop limit the completeness of this analysis.
